Pietro Scilipoti
Overview
Explore the profile of Pietro Scilipoti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montorsi F, Rosiello G, Scilipoti P, Moschini M, Salonia A
Eur Urol
. 2025 Feb;
PMID: 40021399
No abstract available.
2.
Orrason A, Scilipoti P, Garmo H, Gedeborg R, Styrke J, Westerberg M
Scand J Urol
. 2025 Feb;
60:50-58.
PMID: 40013650
Background: Swedish national guidelines provide evidence-based recommendations for standard of care; however, little is known about adherence to them. The aim of this study was to assess adherence to management...
3.
de Angelis M, Siech C, Jannello L, Di Bello F, Penaranda N, Scilipoti P, et al.
Urol Oncol
. 2025 Feb;
PMID: 39986912
Introduction: It is unknown whether sex-related differences in response to neoadjuvant (NAC) or adjuvant chemotherapy (ADJ) exist in urothelial carcinoma patients treated with radical cystectomy (RC). We addressed these knowledge...
4.
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Slusarczyk A, Soria F, et al.
BJU Int
. 2025 Feb;
PMID: 39967051
Objective: To assess the oncological outcomes of patients with high-risk (HR) and very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) treated with upfront radical cystectomy (RC) vs Bacillus Calmette-Guérin (BCG) instillations...
5.
Corsini C, Scilipoti P, Orrason A, Gedeborg R, Westerberg M, Stattin P
JNCI Cancer Spectr
. 2025 Feb;
9(2).
PMID: 39913357
Background: It is unknown if a period of active surveillance before prostatectomy for prostate cancer (PCa) worsens functional outcomes. The aim of this study was to compare functional outcomes after...
6.
Gandaglia G, Barletta F, Scuderi S, Scilipoti P, Rajwa P, Huebner N, et al.
Eur Urol Oncol
. 2025 Jan;
PMID: 39890547
Background And Objective: Extended pelvic lymph node dissection (ePLND) is recommended in selected radical prostatectomy (RP) prostate cancer (PCa) patients for staging purposes. We aim to externally validate available tools...
7.
Longoni M, Rosiello G, Scilipoti P, Belladelli F, Trevisani F, Re C, et al.
Urol Oncol
. 2025 Jan;
PMID: 39880768
Introduction: The American Urology Association (AUA) recently introduced in their guidelines a subtype-agnostic, 4-tiered risk classification score to assess oncologic outcomes after surgery in patients with localized renal cell carcinoma...
8.
Scilipoti P, Garmo H, Gedeborg R, Robinson D, Stattin P, Westerberg M
J Natl Cancer Inst
. 2025 Jan;
PMID: 39821045
Background: There has been a wide range in incidence of prostate-specific antigen (PSA) persistence and relapse after radical prostatectomy (RP) for prostate cancer (PCa). We aimed to describe incidence and...
9.
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, et al.
BJU Int
. 2025 Jan;
PMID: 39797535
Objective: To evaluate the oncological efficacy and safety of sequential intravesical gemcitabine/docetaxel (Gem/Doce) therapy in a European cohort of patients with high-risk and very-high-risk non-muscle-invasive bladder cancer (NMIBC) after previous...
10.
Zaurito P, Scilipoti P, Longoni M, de Angelis M, Re C, Quarta L, et al.
World J Urol
. 2024 Dec;
43(1):52.
PMID: 39739061
Objective: The intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC) prognostic group is heterogeneous. Growing evidence supports the role of active surveillance (AS) for patients with low-risk NMIBC, however, no clear data...